+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019 - Product Thumbnail Image

N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 32 Pages
  • Global
From
Smart Home Opportunity Assessment for Telcos - Product Thumbnail Image

Smart Home Opportunity Assessment for Telcos

  • Report
  • September 2018
  • 20 Pages
  • Global
From
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 83 Pages
  • Global
From
Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 77 Pages
  • Global
From
Allergic Rhinitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Allergic Rhinitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 180 Pages
  • Global
From
Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Rosacea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 85 Pages
  • Global
From
Contact Dermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Contact Dermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 43 Pages
  • Global
From
Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 176 Pages
  • Global
From
Allergic Rhino-Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Allergic Rhino-Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 43 Pages
  • Global
From
Intermediate Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Intermediate Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 37 Pages
  • Global
From
Interleukin 12 Subunit Beta Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Interleukin 12 Subunit Beta Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 52 Pages
  • Global
From
Anterior Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Anterior Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 41 Pages
  • Global
From
Posterior Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Posterior Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 45 Pages
  • Global
From
Grass Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Grass Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 48 Pages
  • Global
From
Cat Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Cat Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 28 Pages
  • Global
From
Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021 - Product Thumbnail Image

Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 847 Pages
  • Global
From
Rheumatoid Arthritis (Immunology) - Drugs in Development, 2021 - Product Thumbnail Image

Rheumatoid Arthritis (Immunology) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Systemic Lupus Erythematosus - Pipeline Review, H2 2020 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 816 Pages
  • Global
From
Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2020 - Product Thumbnail Image

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 693 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2020 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 152 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more